Display options
Share it on

Ann Ib Postgrad Med. 2019 Dec;17(2):111-114.

BETA ENDORPHINS - HOLISTIC THERAPEUTIC APPROACH TO CANCER.

Annals of Ibadan postgraduate medicine

T G Shrihari

Affiliations

  1. Department of Oral Medicine and Oral Oncology, Krishna Devaraya College of Dental Sciences and Hospital, Bangalore, Karnataka, India.

PMID: 32669986 PMCID: PMC7358813

Abstract

AIM: Endorphins are endogenous morphine, neuropeptides, produced in the pituitary gland in response to stress and pain. There are three types of endorphins beta-endorphins, enkephalins, and dynorphins binds to mu, kappa, and delta receptors situated on nervous system and immune cells. Cancer is a major threat to mankind killing millions of people around the world annually. There has been recent advancements in the field of surgery, chemotherapy, and radiotherapy, still the prognosis of cancer patients not improved much with increasing morbidity. We can't kill cancer cells without killing normal cells. Cancer cells and normal cells work alike. The aim of the review was to determine the anticancer activities of beta-endorphins.

MATERIALS AND METHODS: Articles regarding endorphins and its therapeutic application in cancer were searched on PubMed and Google scholar. This review includes studies, reviews, clinical trials and key findings of my research were included in the manuscript.

RESULTS: Beta-endorphin is an abundant endorphin, potent than morphine, synthesized and secreted in the anterior pituitary gland, it is a precursor of POMC (proopiomelanocortin). It has got various mechanisms of action such as analgesic activity, anti-inflammatory activity, immune stimulatory activity, stress buster activity, and euphoric activity.

CONCLUSION: Beta endorphin is an abundant endogenous morphine used for natural holistic preventive, therapeutic, promotive, and palliative treatment of cancer without adverse effects and inexpensive.

© Association of Resident Doctors, UCH, Ibadan.

Keywords: Cortisol; HPA-axis.; IL-1 β; IL-6; Meditation; NF-Kb; STAT-3; Stress; TNF-α

References

  1. Brain Behav Immun. 2015 May;46:87-95 - PubMed
  2. Lancet Oncol. 2010 Jun;11(6):596-601 - PubMed
  3. Cancer Prev Res (Phila). 2015 Jan;8(1):56-67 - PubMed
  4. Evid Based Complement Alternat Med. 2011;2011:481625 - PubMed
  5. PLoS One. 2014 Jul 02;9(7):e100903 - PubMed
  6. Ecancermedicalscience. 2017 Feb 23;11:721 - PubMed
  7. PLoS One. 2012;7(9):e43232 - PubMed
  8. Int J Yoga. 2008 Jul;1(2):45-55 - PubMed
  9. Future Oncol. 2010 Dec;6(12):1863-81 - PubMed
  10. Int J Yoga. 2014 Jul;7(2):147-51 - PubMed
  11. Anesthesiology. 2012 Apr;116(4):940-5 - PubMed
  12. Curr Opin Immunol. 2010 Apr;22(2):231-7 - PubMed
  13. Hawaii Med J. 2010 Mar;69(3):70-1 - PubMed
  14. BMJ. 2017 Jan 25;356:j108 - PubMed
  15. Cancer Res. 2012 Feb 15;72(4):836-40 - PubMed
  16. Trends Immunol. 2003 Aug;24(8):444-8 - PubMed
  17. Brain Behav Immun. 2014 Feb;36:15-26 - PubMed
  18. Biol Psychiatry. 2010 Mar 1;67(5):446-57 - PubMed
  19. Lancet Oncol. 2004 Oct;5(10):617-25 - PubMed
  20. Psychol Bull. 2012 Nov;138(6):1139-71 - PubMed
  21. Front Immunol. 2016 Aug 02;7:293 - PubMed
  22. Front Pharmacol. 2013 Oct 24;4:132 - PubMed
  23. J Clin Oncol. 2014 Apr 1;32(10):1040-9 - PubMed
  24. Cochrane Database Syst Rev. 2011 Aug 10;(8):CD006911 - PubMed
  25. Immunol Cell Biol. 2000 Oct;78(5):562-70 - PubMed

Publication Types